GlassScriptPhysician profile
Eric M Gibney
NPI 1992899207
$2,186.20
in general payments reported to CMS, 2019-2025
23 companies · $782 in 2025
The $782 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $41.79 · 2021: $19.52 · 2022: $151 · 2023: $382 · 2024: $503 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613 · Education: $54.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.03 |
| Education | $54.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.14 | 2019-2025 | Xifaxan, Plenvu |
| Organox LTD | $348.02 | 2025 | |
| Intercept Pharmaceuticals, INC. | $242.09 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $120.11 | 2024-2025 | Iqirvo, Bylvay |
| Veloxis Pharmaceuticals, INC. | $112.36 | 2022-2023 | Envarsus |
| Madrigal Pharmaceuticals | $100.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Astellas Pharma US INC | $100.23 | 2022-2023 | Cresemba |
| Novartis Pharmaceuticals Corporation | $85.49 | 2025 | |
| Mallinckrodt Hospital Products INC. | $80.60 | 2022-2025 | Terlivaz, Acthar |
| Alexion Pharmaceuticals, INC. | $68.93 | 2023-2024 | Ultomiris |
| Travere Therapeutics, INC. | $54.16 | 2023-2025 | Filspari |
| Sanofi-Aventis U.S. LLC | $46.36 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.94 | 2022-2025 | Gattex |
| Baxter Healthcare | $41.79 | 2020 | |
| Orphalan INC | $37.96 | 2024-2025 | Cuvrior |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $26.61 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $23.47 | 2019 | |
| Azurity Pharmaceuticals, INC. | $22.16 | 2025 | |
| Genzyme Corporation | $20.21 | 2019 | |
| Invivyd INC | $19.96 | 2025 | Pemgarda |
| E.R. Squibb & Sons, L.L.C. | $19.24 | 2019 | |
| Melinta Therapeutics, LLC | $17.90 | 2025 | Rezzayo |
| Calliditas Therapeutics US INC. | $14.61 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Gibney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.